- Home
- SGC vs NMRA Comparison
SGC vs NMRA Comparison
Compare SGC & NMRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SGC
- NMRA
- Stock Information
- Founded
- SGC 1920
- NMRA 2019
- Country
- SGC United States
- NMRA United States
- Employees
- SGC N/A
- NMRA N/A
- Industry
- SGC Apparel
- NMRA
- Sector
- SGC Consumer Discretionary
- NMRA
- Exchange
- SGC Nasdaq
- NMRA Nasdaq
- Market Cap
- SGC 281.4M
- NMRA 287.6M
- IPO Year
- SGC N/A
- NMRA 2023
- Fundamental
- Price
- SGC $11.67
- NMRA $1.28
- Analyst Decision
- SGC Strong Buy
- NMRA Buy
- Analyst Count
- SGC 2
- NMRA 8
- Target Price
- SGC $19.00
- NMRA $10.14
- AVG Volume (30 Days)
- SGC 52.0K
- NMRA 1.3M
- Earning Date
- SGC 03-11-2025
- NMRA 03-03-2025
- Dividend Yield
- SGC 4.80%
- NMRA N/A
- EPS Growth
- SGC 35.19
- NMRA N/A
- EPS
- SGC 0.73
- NMRA N/A
- Revenue
- SGC $565,676,000.00
- NMRA N/A
- Revenue This Year
- SGC $5.04
- NMRA N/A
- Revenue Next Year
- SGC $5.54
- NMRA N/A
- P/E Ratio
- SGC $15.99
- NMRA N/A
- Revenue Growth
- SGC 4.12
- NMRA N/A
- 52 Week Low
- SGC $10.90
- NMRA $1.26
- 52 Week High
- SGC $21.80
- NMRA $17.19
- Technical
- Relative Strength Index (RSI)
- SGC 26.41
- NMRA 26.96
- Support Level
- SGC $10.90
- NMRA $1.26
- Resistance Level
- SGC $14.46
- NMRA $1.48
- Average True Range (ATR)
- SGC 0.55
- NMRA 0.13
- MACD
- SGC -0.26
- NMRA 0.08
- Stochastic Oscillator
- SGC 18.73
- NMRA 4.44
About SGC Superior Group of Companies Inc.
Superior Group Of Companies Inc designs apparel products. The company's operating segment includes Branded Products; Healthcare Apparel and Contact Centers. It generates maximum revenue from the Branded Products segment. The Branded Products segment produce and sell customized merchandising solutions, promotional products and branded uniform programs to customers.
About NMRA Neumora Therapeutics Inc.
Neumora Therapeutics Inc is a clinical-stage biopharmaceutical company founded to confront the global brain disease crisis by taking a fundamentally different approach to the way treatments for brain diseases are developed. It has rapidly scaled its therapeutic pipeline, which currently consists of seven clinical and preclinical neuroscience programs that target novel mechanisms of action for a broad range of underserved neuropsychiatric disorders and neurodegenerative diseases. The company expects to continue to progress in the development of its pipeline with the planned initiation of multiple clinical trials across its programs over the next 12 to 18 months, which supports numerous anticipated data readouts.